Fate Therapeutics, Inc.

NASDAQ•FATE

CEO: Dr. Bahram Valamehr M.B.A., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2013-10-01

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

連絡先情報

12278 Scripps Summit Drive, San Diego, CA, 92131, United States

858-875-1800

www.fatetherapeutics.com

時価総額

$131.38M

PER (TTM)

-1.0

17.2

配当利回り

52週高値

$1.94

52週安値

$0.66

52週レンジ

37%

順位62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.9 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$1.37M+0.00%

直近4四半期の推移

EPS

-$0.27+0.00%

直近4四半期の推移

フリーCF

-$24.51M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Loss Significantly Reduced Net loss narrowed to $(136.3) M in 2025 from $(186.3) M in 2024; R&D expenses decreased $27.2 M.

Collaboration Revenue Decline Collaboration revenue dropped $7.0 M to $6.6 M in 2025, reflecting milestone achievement timing in prior year.

FT819 Autoimmunity Pipeline Advances FT819 received RMAT designation; Phase 1 trial ongoing for SLE, showing deep B-cell depletion data.

Cash Position Strengthened Cash, equivalents, and restricted cash totaled $56.9 M as of December 31, 2025, up from $46.3 M.

リスク要因

Substantial Funding Required Operations require substantial additional funding; failure to secure capital risks delaying development or commercialization efforts.

Complex Manufacturing Hurdles iPSC-derived cell therapy manufacturing is complex, subject to scale-up issues, quality control, and supply chain risks.

Stock Price Volatility Risk Stock price subject to fluctuation; principal stockholders own 40.1% and may exert significant control over company.

Regulatory Approval Uncertainty Novel product candidates face uncertain regulatory approval pathways, potentially requiring costly additional clinical studies.

見通し

Advance Autoimmune Disease Trials Plan to continue FT819 multi-center Phase 1 trial expansion across SLE, SSc, AAV, and IIM indications.

Progress Solid Tumor Candidates Continue advancing FT825 (HER2) and FT836 (MICA/MICB) Phase 1 trials for advanced solid tumors.

Complete IND-Enabling Activities Completing IND-enabling activities for FT839 in 2026 to support initial clinical investigation for dual-CAR therapy.

Seek Strategic Partnerships Focus on forming new partnerships for research, development, and commercialization of iPSC-derived cell therapies.

同業比較

売上高 (TTM)

IPHA

$36.93M

-61.2%

ALEC

$21.05M

-79.1%

TNXP

$13.11M

+29.8%

粗利益率 (最新四半期)

MCRB

3251.8%

+0.0pp

APLT

100.0%

+0.0pp

TNXP

80.4%

+13.6pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
PEPG	$351.80M	-2.4	-75.7%	9.8%
FBRX	$331.21M	-9.1	-75.6%	0.0%
ALEC	$246.11M	-1.6	-225.0%	12.4%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-5.6%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-$0.28

売上高:$1.22M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし